JP2023549196A5 - - Google Patents

Info

Publication number
JP2023549196A5
JP2023549196A5 JP2023528189A JP2023528189A JP2023549196A5 JP 2023549196 A5 JP2023549196 A5 JP 2023549196A5 JP 2023528189 A JP2023528189 A JP 2023528189A JP 2023528189 A JP2023528189 A JP 2023528189A JP 2023549196 A5 JP2023549196 A5 JP 2023549196A5
Authority
JP
Japan
Prior art keywords
inhibitor
oral
combination
methoxyurea
tetrahydrothieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549196A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/081304 external-priority patent/WO2022101303A1/en
Publication of JP2023549196A publication Critical patent/JP2023549196A/ja
Publication of JP2023549196A5 publication Critical patent/JP2023549196A5/ja
Pending legal-status Critical Current

Links

JP2023528189A 2020-11-11 2021-11-10 レルゴリクスの投与方法 Pending JP2023549196A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063112523P 2020-11-11 2020-11-11
US63/112,523 2020-11-11
US202163151423P 2021-02-19 2021-02-19
US63/151,423 2021-02-19
PCT/EP2021/081304 WO2022101303A1 (en) 2020-11-11 2021-11-10 Methods of administering relugolix

Publications (2)

Publication Number Publication Date
JP2023549196A JP2023549196A (ja) 2023-11-22
JP2023549196A5 true JP2023549196A5 (enExample) 2024-11-15

Family

ID=78709420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528189A Pending JP2023549196A (ja) 2020-11-11 2021-11-10 レルゴリクスの投与方法

Country Status (3)

Country Link
EP (1) EP4243829A1 (enExample)
JP (1) JP2023549196A (enExample)
WO (1) WO2022101303A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
WO2021069700A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101153042A (zh) 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
SMT202200255T1 (it) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
TWI744224B (zh) 2015-02-26 2021-11-01 日商武田藥品工業股份有限公司 固形製劑
WO2017040841A1 (en) * 2015-09-01 2017-03-09 Abbvie Inc. Methods of administering elagolix
SI3518932T1 (sl) 2016-09-30 2025-03-31 Takeda Pharmaceutical Company Limited Zdravljenje raka prostate
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
EA201992612A1 (ru) * 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
TW201919632A (zh) * 2017-08-18 2019-06-01 美商艾伯維有限公司 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群或子宮腺肌症之醫藥調配物
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
WO2021069700A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Similar Documents

Publication Publication Date Title
KR101812160B1 (ko) 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리
TW200831107A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
JP2005514345A (ja) 更年期以降の女性生殖機能障害の治療のための組成物
Kucuk et al. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers
JP2007512291A (ja) ２種のエストロゲン及び／又はプロゲスチン組成物を含んで成る、２１〜２８日よりも長い期間にわたっての連続ホルモン処理のための医薬製剤
KR20110045065A (ko) 월경 억제, 피임 및 호르몬 대체 요법을 위한 약제 및 이를 투여하는 방법
HU221583B (hu) Térhálósított, polikarbonsavalapú polimer alkalmazása progeszteront tartalmazó vaginális gyógyszerkészítmény előállítására
TW201201799A (en) Parenteral dosage form releasing aromatase inhibitors and progestins to treat endometriosis
JP2005515964A (ja) ホルモン欠乏症を治療するための治療用組成物
US20050101579A1 (en) Endometriosis treatment protocol
FI3634419T3 (fi) Gonadotropiinia vapauttavan hormonin antagonistin käsittävä annostusohjelma kohdun myoomien hoitamiseksi ja kuukautisten aiheuttaman verenhukan vähentämiseksi
WO2003017973A1 (en) A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
JP2019529574A5 (enExample)
CA2601773A1 (en) Compositions of unconjugated estrogens and methods for their use
JP2004519490A (ja) エキセメスタンによるホルモン依存性異常症の組合せ治療方法
US20040082557A1 (en) Methods for treating estrogen-dependent disorders
CA2582530A1 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
TWI354556B (en) Use of a combination of an aromatase inhibitor,a p
US20040142914A1 (en) Extended transdermal contraceptive regimens
KR100772852B1 (ko) 자궁내막증 치료용 약제학적 조성물
JP2004529176A (ja) 頸管熟化を誘導するためのホスホジエステラーゼインヒビターを含む組成物
JP2012077020A (ja) ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
TW200904452A (en) New drospirenone/17β-estradiol regimen, pharmaceutical combination, product and kit for performing this regimen
US11446351B2 (en) Composition for treating one or more estrogen related diseases
JP2001523639A (ja) プロゲストゲン−抗プロゲストゲンレジメン